$Viking Therapeutics(VKTX)$ Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 DaysVK2735 Shown to be Safe and Well-Tolerated in 28-Day Study with Low Rates of GI-Related Adverse Events
Phase 2 Trial in Obesity Planned for 2H24$礼来(LLY)$ $美国生科ETF-SPDR(XBI)$
比预期的要好